NHS Branded Medicines Tranche Framework for London and South of England
Estimated value
—
Awarded value
—
Suppliers
39
Lots
3
Published
20 Aug 2024
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Scope
- Reference
- CM/PHR/22/5689
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2024 to 31 Aug 2026
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 39 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 3 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1 | £129.9m | cancelled |
| 2 | CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2 | £644.0m | cancelled |
| 3 | CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3 | £58.3m | cancelled |